Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it has granted a non-statutory stock option to purchase up to an aggregate of 350,000 shares of common stock of Ocular Therapeutix to a new employee, Philip C.
October 6, 2020
· 6 min read